tbuckley/cabot-search huggingface dataset:
Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis
Authors: Bryant R. England, Jeremy Sokolove, William H. Robinson, Geoffrey M. Thiele, Apar K. Ganti, Harlan Sayles, Kaleb Michaud, Liron Caplan, Lisa A. Davis, Grant W. Cannon, Brian Sauer, Namrata Singh, E. Blair Solow, Andreas M. Reimold, Gail S. Kerr, Pascale Schwab, Josh F. Baker, Ted R. Mikuls
Journal: Arthritis & Rheumatology (2016)

To examine the potential of circulating cytokines and chemokines as biomarkers of cancer mortality risk in patients with rheumatoid arthritis (RA).Male participants in the Veterans Affairs RA registry were followed up from the time of enrollment until death or December 2013. Cytokines and chemokines were measured in banked serum obtained at the time of enrollment, using a bead-based multiplex assay, and a previously developed cytokine score was calculated. Vital status and cause of death were determined through the National Death Index. Associations of cytokines with cancer mortality were examined using multivariable competing-risks regression.Among 1,190 men with RA, 60 cancer deaths (30 of which were attributable to lung cancer) occurred over 5,307 patient-years of follow-up. The patients had a mean age of 64.5 years, had established disease (median duration 8.7 years), were seropositive for rheumatoid factor (81%) or anti-cyclic citrullinated peptide antibody (77%), and frequently had a history of smoking (82% current or former). Seven of 17 analytes examined were individually associated with cancer mortality. The cytokine score was associated with overall cancer (subhazard ratio [SHR] 1.42, 95% confidence interval [95% CI] 1.08-1.85) and lung cancer (SHR 1.86, 95% CI 1.57-2.19) mortality in multivariable analyses. Those in the highest quartile of cytokine scores had a >2-fold increased risk of overall cancer mortality (P = 0.039) and a 6-fold increased risk of lung cancer mortality (P = 0.028) relative to the lowest quartile. A synergistic interaction between current smoking and high cytokine score was observed.Serum cytokines and chemokines are associated with cancer and lung cancer mortality in men with RA, independent of multiple factors including age, smoking status, and prevalent cancer.
Profiling and Validation of the Circular RNA Repertoire in Adult Murine Hearts
Authors: Tobias Jakobi, Lisa F. Czaja-Hasse, Richard Reinhardt, Christoph Dieterich
Journal: Genomics Proteomics & Bioinformatics (2016)

Abstract For several decades, cardiovascular disease has been the leading cause of death throughout all countries. There is a strong genetic component to many disease subtypes (e.g., cardiomyopathy) and we are just beginning to understand the relevant genetic factors. Several studies have related RNA splicing to cardiovascular disease and circular RNAs (circRNAs) are an emerging player. circRNAs, which originate through back-splicing events from primary transcripts, are resistant to exonucleases and typically not polyadenylated. Initial functional studies show clear phenotypic outcomes for selected circRNAs. We provide, for the first time, a comprehensive catalogue of RNase R-resistant circRNA species for the adult murine heart. This work combines state-of-the-art circle sequencing with our novel DCC software to explore the circRNA landscape of heart tissue. Overall, we identified 575 circRNA species that pass a beta-binomial test for enrichment (false discovery rate of 1%) in the exonuclease-treated sequencing sample. Several circRNAs can be directly attributed to host genes that have been previously described as associated with cardiovascular disease. Further studies of these candidate circRNAs may reveal disease-relevant properties or functions of specific circRNAs.
Acute Esophagitis and Concomittant Chemoradiotherapy with Navelbine. Results from Narlal, a Phase II Randomized Trial
Authors: Tine Schytte, Marianne Knap, Azza Ahmed Khalil, Christa H. Nyhus, Tine McCulloch, Bente Holm, Carsten Brink, Olfred Hansen
Journal: Journal of Thoracic Oncology (2013)
A CASE OF SEVERE ASCARIS INFESTATION
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTU-065 The influence of smoking on need for surgery and post-operative outcomes in crohn’s disease
Authors: A O’Connor, J Taylor, F Abid, A Crudeli, T Clark, N Scott, PJ Hamlin, AC Ford
Journal: Gut (2015)

<h3>Introduction</h3> Up to 70% of patients with Crohn’s disease (CD) may require surgery at some point in their lives and it is estimated 39% may require several surgeries. Indications for surgery include failure of medical treatment, bowel obstruction, fistula or abscesss formation. The most common surgical procedure is resection. Smoking is a recognised risk factor for requiring surgery in Crohn’s and also predicts post-operative recurrence. <h3>Method</h3> We aimed to examine the effect of tobacco smoking on the risk for surgery and it’s influence on post-operative outcomes in patient with CD. We performed a retrospective analysis by initially identifying cases by interrogating the pathology database over a five year period from 2009 to 2013 and further data was then extracted by chart review. <h3>Results</h3> 152 resections took place over the study period, 6 of these had taken place on children and these were not analysed for smoking history. Median follow-up was 32 months (range 1 to 69 months). 31.5% (n = 46) of adults were active smokers at time of surgery. Among those having repeat resections 24.1% were active smokers. Smokers were more likely to have required emergency surgery than non-smokers (34.8% vs 30.0%). Median disease duration prior to surgery (among patients having first surgery) was shorter in the smoking group (2.5 vs 4 years). Smokers were more likely to have penetrating disease (32% vs 25.5%). The rate of steroid-free, further resection-free survival at end of follow up was higher for non-smokers (66% vs 63.0%). 68 patients had colonoscopies during follow-up, in 4 cases a Rutgeerts score could not be ascertained from the report. 43.8% (7/16) of smokers had endoscopic recurrence with Rutgeerts score i2 or greater compared to 45.8% (22/48) of non-smokers. <h3>Conclusion</h3> Compared to the background rate of smoking among adults in the UK (18.7%), smokers are over-represented in this CD surgery cohort. In this small, retrospective cohort smokers were more likely to have penetrating disease, come to surgery sooner and require emergency surgery than non-smokers. Outcomes were broadly similar for smokers and non-smokers with a minor benefit for achieving steroid free, further resection-free survival in the non-smoking group and slightly less endoscopic recurrence among smokers. The lower rate of smoking among those having repeat resections compared to first resections may indicate that a CD resection is a motivating factor to give up smoking. <h3>Disclosure of interest</h3> None Declared.
Survival in Childhood Malignancies: Assessment of the Influence of Age, Sex, and Tumor Type, With Emphasis on “Long-Term Survivors”&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: B Modan, I Virag, M Modan
Journal: JNCI Journal of the National Cancer Institute (1969)

Survival data (or a 5-year period were analyzed for all newly diagnosed malignancies in Israel in children under 15. Three major survival patterns were evident: an extremely poor survivorship (or leukemia, a good survivorship (or retinoblastoma, and an intermediate position (or the rest of the tumor categories. Survival was appreciably affected by age and sex: With most types of neoplasms, particularly lymphomas, survival was consistently better in girls. The exceptions were patients with leukemia, in which survival was similar in both sexes, or with brain tumor, in which boys had considerably better survival. The tumor distribution was similar in both sexes. Median survival time increased gradually (rom the group under 1 year old to the 10- to 14-year-old group. This improvement with age was partly due to a shift toward tumors with better survivorship and partly to an increasing survival with age in each of the specific tumor types. In all tumor categories the probability of dying within a fixed time interval became progressively lower (or those surviving longer after diagnosis. Eventually, in all tumor types except leukemia, the annual probability of death among those who survived (or a certain time period dropped below 0.10 and probably considerably less in some categories. These patients are referred to as long-term survivors. The length of time from diagnosis after which survivors can be considered long-term, and the percentage of diagnosed cases likely to become long-term survivors, varied according to tumor type, sex, and age. The survival patterns observed indicate the existence of a variable disease course ranging from the very fulminant to the benign.
Exercise pulmonary haemodynamics: a test in search of purpose
Authors: J. Gerry Coghlan, Harm Jan Bogaard
Journal: European Respiratory Journal (2016)

Ever since the entity of "exercise induced pulmonary hypertension" was banned from the pulmonary hypertension (PH) dictionary in 2008, during the World Symposium on Pulmonary Hypertension at Dana Point (CA, USA) [1], there has been a concern that by just measuring pulmonary haemodynamics at rest, many patients with subclinical pulmonary vascular disease go unrecognised. This could be harmful, if subjects with an abnormal pulmonary haemodynamic response to exercise are at particular risk of developing PH and that early recognition of PH in these patients would improve their outcome. It may even be that the presence of an abnormal pulmonary haemodynamic response to exercise represents a treatable condition. To date, there is no proof to validate any of these assumptions. Borderline PH at rest predicts abnormal exercise pulmonary haemodynamics and exercise intolerance <http://ow.ly/YVQTC>
Content, Readability, and Understandability of Dense Breast Notifications by State
Authors: Nancy R. Kressin, Christine M. Gunn, Tracy A. Battaglia
Journal: JAMA (2016)

Elizabeth A. Rafferty, MD; Melissa A. Durand, MD; Emily F. Conant, MD; Debra Somers Copit, MD; Sarah M. Friedewald, MD; Donna M. Plecha, MD; Dave P. Miller, MS
Micropatterning Facilitates the Long‐Term Growth and Analysis of iPSC‐Derived Individual Human Neurons and Neuronal Networks
Authors: Lena F. Burbulla, Kristin G. Beaumont, Milan Mrksich, Dimitri Krainc
Journal: Advanced Healthcare Materials (2016)

The discovery of induced pluripotent stem cells (iPSCs) and their application to patient-specific disease models offers new opportunities for studying the pathophysiology of neurological disorders. However, current methods for culturing iPSC-derived neuronal cells result in clustering of neurons, which precludes the analysis of individual neurons and defined neuronal networks. To address this challenge, cultures of human neurons on micropatterned surfaces are developed that promote neuronal survival over extended periods of time. This approach facilitates studies of neuronal development, cellular trafficking, and related mechanisms that require assessment of individual neurons and specific network connections. Importantly, micropatterns support the long-term stability of cultured neurons, which enables time-dependent analysis of cellular processes in living neurons. The approach described in this paper allows mechanistic studies of human neurons, both in terms of normal neuronal development and function, as well as time-dependent pathological processes, and provides a platform for testing of new therapeutics in neuropsychiatric disorders.
<i>In vivo</i> and <i>in vitro</i> efficacy of capecitabine (X) + tamoxifen (TAM) in breast cancer (BC)
Authors: K. Mori, Y. Yamaguchi, N. Sawada, K. Kondoh, S. Hayashi
Journal: Journal of Clinical Oncology (2007)

21092 Background: In vitro studies in BC cell lines suggested antagonism between TAM and 5-FU. Thymidine phosphorylase (TP) activates X to 5-FU in tumors. X activity correlates with tumor TP concentrations in vivo. Methods: We studied antitumor efficacy of X + TAM in vivo and in vitro in human BC models. Nude mice were inoculated s.c. with estradiol, then MCF-7 cells 1 day later. When tumors were ∼300 mm 3 , mice received 6 weeks’ oral vehicle (control), X (d1–14 q21d) at MTD (539 mg/kg) or 2/3 MTD, and/or TAM at 100 or 30 mg/kg/d. We also analyzed impact of 5-FU and doxifluridine (5'-DFUR, an intermediate of X) + TAM on estrogen receptor (ER) signals in an in-vitro culture system. ER signals were monitored by expression of green fluorescent protein (GFP) in MCF-7 BC cells transfected with the estrogen-responsive element (ERE)-GFP gene (MCF-7-E10). GFP expression was induced in MCF-7-E10 cells in the presence of estradiol at 3 pM or BC tissue supernatant. Results: X at 2/3 MTD + TAM 30 mg/kg were significantly more active than the highest dose of X or TAM alone. Tumor TP concentrations were significantly higher in TAM- than vehicle-treated mice. In the ER signal system, GFP expression of MCF-7-E10 was reduced by 4-hydroxytamoxifen (4-OHT, active form of TAM) at 0.01 and 0.1 nM. When added to 4-OHT, 5-FU 0.3–30 μM or 5'-DFUR 3–10 μM reduced GFP expression more than either agent alone. In vitro, 5-FU and 5'-DFUR inhibited proliferation of MCF-7-E10 cells regardless of 4-OHT. Additive effects could not be confirmed as 4-OHT alone showed only marginal anti- proliferative activity at 0.01–0.1 nM. Conclusion: X and TAM are not antagonistic in this model. TAM may augment X activity via TP upregulation in BC tissues. TAM and X intermediates showed no clear antagonism in vitro in an ER signal system. All-oral X + TAM merits evaluation as combination therapy in breast cancer. [Table: see text]
42P Atopy and cancer risk: Insights from a prospective study on serum specific and total immunoglobulin E
Authors: W. Wulaningsih, H. Garmo, L. Holmberg, H. Malmstrom, M. Lambe, N. Hammar, G. Walldius, I. Jungner, M. van Hemelrijck
Journal: Annals of Oncology (2015)
Triple-negative breast cancer and likelihood of nodal metastates.
Authors: Alexandra Gangi, James Mirocha, Trista Leong, Armando E. Giuliano
Journal: Journal of Clinical Oncology (2013)

50 Background: Axillary lymph node metastases are a prognostic indicator for breast cancer. Studies suggest that breast cancer subtypes are associated with the presence of lymph node (LN) metastases. The purpose of this study was to determine if patients with triple negative breast cancer (TNBC) have a higher risk of LN metastases than those with non-TNBC. Methods: Prospective database review identified 2,967 female patients with invasive breast cancer treated with mastectomy or breast conserving surgery (BCS) between January 2000 and May 2012. Only patients who underwent sentinel node biopsy (SNB) and/or axillary lymph node dissection (ALND) were included. Those receiving neoadjuvant therapy were excluded. Patient and tumor characteristics evaluated included age, race, tumor size, grade, stage, histologic subtype, presence of lymphovascular invasion (LVI), estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (HER2) status. Results: BCS was performed in 1,889 and mastectomy in 1,078 patients. Breakdown by subtype included 2,201 (74%) patients with Luminal A, 344 (12%) with Luminal B, 144 (5%) with HER2, and 278 (9%) with TNBC. SNB was performed in 1,094 (37%), ALND in 756 (25%), and 1,117 (38%) patients had both. LN metastases were detected in 1050 (35%) patients. The LN positivity rate varied across subtypes with 734/2,201 (33%) in Luminal A, 143/344 (42%) in Luminal B, 108/278 (39%) in TNBC, and 65/144 (45%) in HER-2 (p = 0.0007). However, on multivariable analysis, there was no difference in LN positivity among subtypes (p=0.24). Only age &lt; 50 (HR 1.5, CI 1.3 to 1.8), grade 2 or 3 tumors (HR 1.8, CI 1.4 to 2.5), size greater than 2cm (HR 3.2, CI 2.7 to 3.9), and presence of LVI (HR 3.9, CI 2.4 to 6.3) were significant predictors of LN positivity. Four or more involved nodes were seen most commonly in the HER2 (28/144; 19%) and Luminal B (47/344; 14%) subtypes, but not TNBC (26/278; 9%) or Luminal A (199/2201; 9%) (p &lt; 0.0001). Conclusions: Predictors of LN metastases include younger age, higher grade, larger tumor size, and presence of LVI. Patients with TNBC are not more likely to have involved nodes than those with non-TNBC.
Extranuclear Actions of the Androgen Receptor Enhance Glucose-Stimulated Insulin Secretion in the Male
Authors: Guadalupe Navarro, Weiwei Xu, David A. Jacobson, Barton Wicksteed, Camille Allard, Guanyi Zhang, Karel De Gendt, Sung Hoon Kim, Hongju Wu, Haitao Zhang, Guido Verhoeven, John A. Katzenellenbogen, Franck Mauvais-Jarvis
Journal: Cell Metabolism (2016)
TCTAP C-008 Primary PCI in Single Coronary Artery with Acute Myocardial Infarction
Authors: Yosua Arthur Iskandar, Monique Priscilla Fransiska Rotty, Soetandar Widjaja, Hendro Adi Kuncoro, Johan Senihardja, Rizki Francis Pandelaki, Benny Mulyanto Setiadi, Bambang Budiono, Janry Anton Pangemanan, Agnes Lucia Panda
Journal: Journal of the American College of Cardiology (2016)
Phenotypic analysis of acute lymphoblastic leukemia (ALL) cells which are classified as non-T non-B and negative for common ALL antigen
Authors: K Kita, K Nasu, H Kamesaki, S Doi, H Tezuka, E Tatsumi, S Fukuhara, M Nishikori, H Uchino, S Shirakawa
Journal: Blood (1985)
Prognosis and Treatment Beyond Progression to Braf Inhibitors in Patients with Braf-Mutated Metastatic Melanoma
Authors: D. Bafaloukos, H. Linardou, A. Tarampikou, P. Gouveris, A. Laskarakis, A. Molfeta, A. Hatzigeorgiou, E. Bousboukea, D. Kanaloupiti
Journal: Annals of Oncology (2014)
Double Blind Randomized Phase III Study of Maintenance Pazopanib® (Pz) Versus Placebo (P) in Non Small Cell Lung Cancer (Nsclc) Patients (Pts) Non Progressive After First Line Chemotherapy [Ct] (Eortc Lung Cancer Group, 08092): Mapping
Authors: M.E.R. O'Brien, R. Gaafar, B. Hasan, J. Menis, T. Cufer, S. Popat, P. Woll, V. Surmont, V. Georgoulias, A. Montes, F. Blackhall, I. Hennig, G. Schmid-Bindert, P. Baas
Journal: Annals of Oncology (2014)
Clinical trials: registration and transparency
Authors: Giovanni Sotgiu, Marc Humbert, Anh Tuan Dinh-Xuan, Giovanni Battista Migliori
Journal: European Respiratory Journal (2016)

Today, scientific evidence drives medical practice. Translational, clinical and operational research provide, day after day, new information to clinicians, public health specialists, policymakers and health officials, improving their management of single patients and of the general population. However, it is not easy to identify the best sources of information within a growing number of journals and scientific articles.
Biweekly alternating FOLFOX and FOLFIRI in patients with previously untreated, advanced colorectal cancer (ACC): Updated results
Authors: C. Fernandez-Martos, J. Aparicio, J. M. Vicent, I. Maestu, C. Llorca, I. Busquier, J. M. Campos, D. Asensio, R. Romero
Journal: Journal of Clinical Oncology (2004)

3563 Background: Irinotecan (CPT-11) and oxaliplatin (L-OHP) are active agents in ACC. Combining each with continuous infusion (CI) 5-fluorouracil (5-FU) provides an objective response rate approaching 50%, with acceptable toxicity in first line treatment. The objective of this study was to assess the efficacy and tolerance of a protocol that alternates Gramont's LV5FU2 schedule plus L-OHP (FOLFOX-4) with the same 5-FU regimen plus CPT-11 (FOLFIRI) on a biweekly basis. Methods: Patients with previously untreated, histologically confirmed, unresectable ACC were included if they had measurable disease; adequate bone marrow, liver, and renal functions; PS (ECOG) 0–2; life expectancy > 3 months, and written informed consent. Treatment consisted of 2-hours CI Folinic acid (FA) 200 mg/m2, bolus 5-FU 400 mg/m2 and 22-hours CI 5-FU 600 mg/m2, all on days 1 and 2 every 14 days. CPT-11 (180 mg/m2) and L-OHP (85 mg/m2) were given on day 1 of alternating chemotherapy administrations. 1 chemotherapy cycle (FOLFOX-FOLFIRI) takes 28 days. Response evaluation was scheduled every 3 cycles. Results: 79 patients were enrolled (42 males, 37 females). Median age was 61 years (range 39–77). On PS, patients were distributed as follows: 0 (43.8%), 1 (47.5%), and 2 (8.8%). The number of metastatic sites was 1 (39.7%) or >1 (60.3%). 745 infusions were administered in 77 patiens who were evaluable for toxicity (median 5 cycles per patient, range 1–9 cycles). Response evaluation was performed in 45 patients. 8.9% of patients showed a complete response and 51.1% showed a partial response. Disease was stabilized in 15.6% of patients and in 24.4% of patients disease progression was observed. Of the 77 patients evaluated for toxicity, 47.5% had grade 3–4 toxicity. The most common grade 3–4 adverse events were: neutropenia 28.9%, diarrhea 21.1%, pain 6.6%, leucopenia 5.3%, anemia 5.3%, asthenia 3.9%, infection 2.6%, febrile neutropenia 2.6%, nausea/vomiting 2.6%, neurotoxicity 1.3% and transaminase increase 1.3%. Conclusions: The updated results of this study suggest that this regimen is effective and shows a good safety profile. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Prasfarma/Almirall
Cancer Stem Cell Hypothesis Evolves With Emerging Research
Authors: Vicki Brower
Journal: JNCI Journal of the National Cancer Institute (2016)

Patients with stage II and III colorectal cancer whose tumors possessed more stem cell-like properties had worse 5-year disease-free survival rates than individuals with more differentiated tumors, 6.9% compared to 93.1%, according to a new study.The presence of the CDX2 transcription factor in tumors, which drives differentiation of intestinal cells, statistically correlated with the least aggressive cancers and highest rates of survival in the validation set.